Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$64.14 USD

64.14
1,566,779

+1.12 (1.78%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $64.15 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Do Options Traders Know Something About Incyte (INCY) Stock We Don't?

Investors need to pay close attention to Incyte (INCY) stock based on the movements in the options market lately.

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of -333.33% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

INCY or MYGN: Which Is the Better Value Stock Right Now?

INCY vs. MYGN: Which Stock Is the Better Value Option?

Incyte (INCY) Gains 19.6% in Three Months: Here's Why

Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Company News for July 10, 2024

Companies In The Article Are:INCY, LW,PATH and HELE

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

Agilent (A) Boosts Reach to Lab Researchers With New Devices

Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week

Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.

Company News For May 14, 2024

Companies In The Article Are:SQSP,INCY, WBA and GOOG.

Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.

Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.